ArticleActa psychiatrica Scandinavica2026
Selective Serotonin Reuptake Inhibitor Treatment in Adolescence and Subsequent Risk of Nonaffective Psychosis: A Quasi-Experimental Study.
Article in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antidepressants and Psychosis Risk: Disentangling Causal Effects From Prognostic Signals.Acta psychiatrica Scandinavica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePsychotic disorders are frequently preceded by common mental disorders (CMDs), like depression and anxiety. It remains unclear whether treating CMDs in adolescence can reduce subsequent psychosis risk. We applied quasi-experimental methods to national register data to assess whether a causal relationship exists between selective serotonin reuptake inhibitor (SSRI) treatment in adolescence and subsequent risk of psychosis.
methodsUsing the secure anonymized information linkage databank, we identified individuals living in Wales (born between 1991 and 1998) with depression who attended Child and Adolescent Mental Health Services. We employed an instrumental variable (IV) analysis, using regional variation in SSRI prescribing practice to estimate the causal effect of cumulative SSRI treatment on psychosis risk, applying two-stage least squares and IV probit models.
resultsOur cohort included n = 6615 individuals with adolescent depression. We found no evidence that cumulative SSRI prescription influenced the psychosis risk across intervention windows (1 year: β: 0.114, CI: -0.049, 0.276; 2 years: β 0.062, CI: -0.114, 0.239; 3 years: β 0.021, CI: -0.125, 0.168).
conclusionThis quasi-experimental study found no evidence of a causal relationship between SSRI treatment in adolescence and later psychosis risk. Our findings do not support the hypothesis that SSRI treatment of CMDs in adolescence prevents later psychosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.